In a major immunopharmacological study involving
10,882 subjects, senior author Prof. Rabih Halwani has
concluded the proven efficacy of Sotrovimab in its use for
Covid-19 patients. As the largest study of its kind in the
country, the monoclonal antibody was found to reduce
the risk of disease progression and was described as a
recommended alternative to anti-viral therapy.